Stocks · News reference
HC Wainwright & Co. analyst Matthew Caufield reiterates Kodiak Sciences (NASDAQ:KOD) with a Buy and maintains $58 price target.
Reference Details
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
Keep reading
Kodiak Sciences (NASDAQ:KOD) reported quarterly losses of $(1.05) per share which missed the analyst consensus estimate of $(0.95) by 10.53 percent. This is a 1.94 percent decrease over losses of $(1.03) per share from
Filed: 2026-08-13 AccNo: 0001193125-26-349107 Size: 309 KB Item 2.02: Results of Operations and Financial Condition Item 9.01: Financial Statements and Exhibits
Phase 3 ALTO trial designed to demonstrate superiority of KSI-501 versus aflibercept in patients with diabetic macular edemaPALO ALTO, Calif., Aug. 10, 2026 /PRNewswire/ -- Kodiak Sciences Inc. (NASDAQ:KOD), a